China Concludes First-Ever Securities Class Action With a Slap-on-the-Wrist Order

In China's first-ever securities class action, Kangmei Pharmaceuticals has been ordered to pay $385 million as compensation—just enough for 50,000 investors to recoup their losses.

2 minute readNovember 22, 2021 at 11:35 AM

Jessica Seah

China Concludes First-Ever Securities Class Action With a Slap-on-the-Wrist Order

(This article was first published on Law.com International.)

Kangmei Pharmaceuticals, one of China's largest Chinese medicine makers, has been ordered to pay its 50,000 investors $385 million as compensation for their losses on their company's stock.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)